Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Equities researchers at Wedbush issued their FY2025 EPS estimates for Foghorn Therapeutics in a research report issued to clients and investors on Friday, March 19th. Wedbush analyst R. Driscoll expects that the company will earn ($1.86) per share for the year. Separately, Zacks Investment Research upgraded shares of Foghorn Therapeutics […]